{
    "nct_id": "NCT03539744",
    "official_title": "A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "* Documented diagnosis of multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria.\n* Measurable disease at screening as defined per protocol.\n* Has received at least 2 prior lines of therapy as described in the protocol.\n* Has had documented disease progression on or within 60 days after completion of the last therapy.\n* Has received at least 2 consecutive cycles of lenalidomide and be relapsed/refractory to lenalidomide, as defined per protocol.\n* Has received at least 2 consecutive cycles of a proteasome inhibitor (PI).\n* Has t(11;14)-positive status determined by an analytically validated fluorescent in situ hybridization (FISH) assay per centralized laboratory testing.\n* An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.\n* Laboratory values (liver, kidney and hematology laboratory values) that meet criteria as described per protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of treatment with venetoclax or another B-Cell Lymphoma (BCL)-2 inhibitor or pomalidomide.\n* History of other active malignancies, including myelodysplastic syndromes (MDS), within the past 3 years (exceptions described in the protocol).\n* Evidence of ongoing graft-versus-host disease (GvHD) if prior stem cell transplant (SCT).\n* Prior treatment with any of the following: allogeneic or syngeneic SCT within 16 weeks prior to randomization; or autologous SCT within 12 weeks prior to randomization.\n* Known central nervous system involvement of MM.\n* Concurrent conditions as listed in the protocol.",
    "miscellaneous_criteria": ""
}